PepGen Inc.
NMS: PEPGLive Quote
About PepGen Inc.
Healthcare
Biotechnology
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
📊 Fundamental Analysis
PepGen Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -67.4%, which indicates that capital utilization is currently under pressure.
At a current price of $1.64, PEPG currently trades near the bottom of its 52-week range (9%), indicating potential value or weakness (Range: $1.01 - $7.80).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$95.45M
Trailing P/E
--
Forward P/E
-1.41
Beta (5Y)
2.34
52W High
$7.80
52W Low
$1.01
Avg Volume
1.31M
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App